Medipharm Labs Corp
TSX:LABSView on OTCQB

  • LAST PRICE
    0.0700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0650/ 1,033
  • Ask / Lots
    0.0700/ 115
  • Open / Previous Close
    --- / 0.0700
  • Day Range
    ---
  • 52 Week Range
    0.0600
    0.1000
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:22AM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: HMMJ, LABS
      07:22 AM EST, 11/14/2024 (MT Newswires) -- ...

    • 7:00AM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: MEDIF

      Strong Growth in International GMP Medical Markets

      MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and nine months ended September 30, 2024.

    • 7:00AM ET on Thursday Nov 14, 2024 by CNW Group
      Companies Mentioned: MEDIF

      COMTEX_459794885/2669/2024-11-14T07:00:50

    • 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: LABS

      should not be considered in isolation from, or as a substitute for, analysis of the Company's results as reported under IFRS. Adjusted EBITDA, as used within the Company's disclosure, may not be directly comparable to Adjusted EBITDA used by other reporting issuers. Adjusted EBITDA does not have a standardized meaning and the Company's method of calculating such non-IFRS measure may not be comparable to calculations used by other companies bearing the same description.

    • 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: LABS

      necessary resources and approval requirements to launch products into any future cannabis-regulated US market; Australian medical cannabis market size and growth potential; international cannabis market size and growth potential; ecommerce platform growth potential; future patient retention in the Company's medical cannabis clinics; ability to overcome regulatory, validation or stability challenges; ability to optimize facility utilization; ability to streamline operations; ability to deliver cost savings; ability to deliver better service; and ability to grow profitable sales. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.